Z H Eng, M M Ahmad Jefry, K L Ng, A Abdul Aziz, S Mat Junit
{"title":"由BRAFV600E、NRASQ61R和NRASQ61H组成的突变面板复制了一组马来西亚患者的回顾性组织病理学检查结果,用于区分良性甲状腺肿和恶性甲状腺乳头状癌。","authors":"Z H Eng, M M Ahmad Jefry, K L Ng, A Abdul Aziz, S Mat Junit","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Thyroid malignancy status is usually confirmed through histopathological examination (HPE) following thyroidectomy. In Malaysia, the application of molecular markers in pre-operative diagnosis of thyroid cancer remains unexplored. In this study, BRAF and NRAS gene mutation panel was assessed, and the results were compared with retrospective HPE findings. Malaysian patients with benign goitre (BTG: n=33) and papillary thyroid cancer (PTC: n=25; PTCa: n=20, PTCb: n=5) were recruited at Universiti Malaya Medical Centre from September 2019 to December 2022. PCR-direct DNA sequencing of BRAF<sup>V600</sup>, NRAS<sup>G12</sup>, NRAS<sup>G13</sup>, and NRAS<sup>Q61</sup> was conducted on DNA extracted from the patients' thyroid tissue specimens following thyroidectomy and HPE. BRAF<sup>V600E</sup> and NRAS<sup>Q61R</sup> mutations showed absolute PTC-specificity with PTC-sensitivity of 32% and 28%, respectively. NRAS<sup>Q61H</sup> demonstrated lower PTC-specificity (94%) but higher PTC-sensitivity (72%) compared to the BRAF<sup>V600E</sup> and NRAS<sup>Q61R</sup> mutations. Although the NRAS<sup>G12</sup> and NRAS<sup>G13</sup> variants were absent in this study, a novel NRAS<sup>V14D</sup> mutation was detected in a PTCa patient. Unlike PTCb, coexistence of BRAF<sup>V600E</sup> and NRAS<sup>Q61</sup> variants was commonly observed among the PTCa patients. Notably, all PTCb patients had NRAS<sup>Q61H</sup> mutation with one patient carried both the NRAS<sup>Q61H</sup> and BRAF<sup>V600E</sup> mutations. Association analysis revealed potential link between gender, BRAF<sup>V600E</sup> mutation and lymph node metastasis. In conclusion, mutation panel comprising BRAF<sup>V600E</sup>, NRAS<sup>Q61R</sup>, and NRAS<sup>Q61H</sup> did not discriminate the two PTC subtypes but replicated the retrospective HPE findings in differentiating BTG from PTC. The application of this mutation panel in pre-operative diagnosis of thyroid nodules requires further validation in a larger sample size, preferably incorporating fineneedle aspirate biopsies.</p>","PeriodicalId":48723,"journal":{"name":"Malaysian Journal of Pathology","volume":"45 3","pages":"375-390"},"PeriodicalIF":0.6000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A mutation panel comprising BRAF<sup>V600E</sup>, NRAS<sup>Q61R</sup>, and NRAS<sup>Q61H</sup> replicated retrospective histopathological examination findings in differentiating benign goitre from malignant papillary thyroid cancer in a cohort of Malaysian patients.\",\"authors\":\"Z H Eng, M M Ahmad Jefry, K L Ng, A Abdul Aziz, S Mat Junit\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Thyroid malignancy status is usually confirmed through histopathological examination (HPE) following thyroidectomy. In Malaysia, the application of molecular markers in pre-operative diagnosis of thyroid cancer remains unexplored. In this study, BRAF and NRAS gene mutation panel was assessed, and the results were compared with retrospective HPE findings. Malaysian patients with benign goitre (BTG: n=33) and papillary thyroid cancer (PTC: n=25; PTCa: n=20, PTCb: n=5) were recruited at Universiti Malaya Medical Centre from September 2019 to December 2022. PCR-direct DNA sequencing of BRAF<sup>V600</sup>, NRAS<sup>G12</sup>, NRAS<sup>G13</sup>, and NRAS<sup>Q61</sup> was conducted on DNA extracted from the patients' thyroid tissue specimens following thyroidectomy and HPE. BRAF<sup>V600E</sup> and NRAS<sup>Q61R</sup> mutations showed absolute PTC-specificity with PTC-sensitivity of 32% and 28%, respectively. NRAS<sup>Q61H</sup> demonstrated lower PTC-specificity (94%) but higher PTC-sensitivity (72%) compared to the BRAF<sup>V600E</sup> and NRAS<sup>Q61R</sup> mutations. Although the NRAS<sup>G12</sup> and NRAS<sup>G13</sup> variants were absent in this study, a novel NRAS<sup>V14D</sup> mutation was detected in a PTCa patient. Unlike PTCb, coexistence of BRAF<sup>V600E</sup> and NRAS<sup>Q61</sup> variants was commonly observed among the PTCa patients. Notably, all PTCb patients had NRAS<sup>Q61H</sup> mutation with one patient carried both the NRAS<sup>Q61H</sup> and BRAF<sup>V600E</sup> mutations. Association analysis revealed potential link between gender, BRAF<sup>V600E</sup> mutation and lymph node metastasis. In conclusion, mutation panel comprising BRAF<sup>V600E</sup>, NRAS<sup>Q61R</sup>, and NRAS<sup>Q61H</sup> did not discriminate the two PTC subtypes but replicated the retrospective HPE findings in differentiating BTG from PTC. The application of this mutation panel in pre-operative diagnosis of thyroid nodules requires further validation in a larger sample size, preferably incorporating fineneedle aspirate biopsies.</p>\",\"PeriodicalId\":48723,\"journal\":{\"name\":\"Malaysian Journal of Pathology\",\"volume\":\"45 3\",\"pages\":\"375-390\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Malaysian Journal of Pathology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Malaysian Journal of Pathology","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PATHOLOGY","Score":null,"Total":0}
A mutation panel comprising BRAFV600E, NRASQ61R, and NRASQ61H replicated retrospective histopathological examination findings in differentiating benign goitre from malignant papillary thyroid cancer in a cohort of Malaysian patients.
Thyroid malignancy status is usually confirmed through histopathological examination (HPE) following thyroidectomy. In Malaysia, the application of molecular markers in pre-operative diagnosis of thyroid cancer remains unexplored. In this study, BRAF and NRAS gene mutation panel was assessed, and the results were compared with retrospective HPE findings. Malaysian patients with benign goitre (BTG: n=33) and papillary thyroid cancer (PTC: n=25; PTCa: n=20, PTCb: n=5) were recruited at Universiti Malaya Medical Centre from September 2019 to December 2022. PCR-direct DNA sequencing of BRAFV600, NRASG12, NRASG13, and NRASQ61 was conducted on DNA extracted from the patients' thyroid tissue specimens following thyroidectomy and HPE. BRAFV600E and NRASQ61R mutations showed absolute PTC-specificity with PTC-sensitivity of 32% and 28%, respectively. NRASQ61H demonstrated lower PTC-specificity (94%) but higher PTC-sensitivity (72%) compared to the BRAFV600E and NRASQ61R mutations. Although the NRASG12 and NRASG13 variants were absent in this study, a novel NRASV14D mutation was detected in a PTCa patient. Unlike PTCb, coexistence of BRAFV600E and NRASQ61 variants was commonly observed among the PTCa patients. Notably, all PTCb patients had NRASQ61H mutation with one patient carried both the NRASQ61H and BRAFV600E mutations. Association analysis revealed potential link between gender, BRAFV600E mutation and lymph node metastasis. In conclusion, mutation panel comprising BRAFV600E, NRASQ61R, and NRASQ61H did not discriminate the two PTC subtypes but replicated the retrospective HPE findings in differentiating BTG from PTC. The application of this mutation panel in pre-operative diagnosis of thyroid nodules requires further validation in a larger sample size, preferably incorporating fineneedle aspirate biopsies.
期刊介绍:
The Malaysian Journal of Pathology is the official journal of the College of Pathologists, Academy of Medicine Malaysia. The primary purpose of The Journal is to publish the results of study and research in Pathology, especially those that have particular relevance to human disease occurring in Malaysia and other countries in this region. The term PATHOLOGY will be interpreted in its broadest sense to include Chemical Pathology, Cytology, Experimental Pathology, Forensic Pathology, Haematology, Histopathology, Immunology, Medical Microbiology and Parasitology. The Journal aims to bring under one cover publications of regional interest embracing the various sub-specialities of Pathology. It is expected that the articles published would be of value not only to pathologists, but also to medical practitioners in search of a scientific basis for the problems encountered in their practice, and to those with an interest in diseases which occur in the tropics.